Eur Respir J 2004; 24:107-115
Copyright ©ERS Journals Ltd 2004
Increase in laminin expression in allergic airway remodelling and decrease by dexamethasone
P.E. Christie1,
M. Jonas2,
C-H. Tsai3,
E.Y. Chi2 and
W.R. Henderson, Jr1
Depts of 1 Medicine and 2 Pathology, University of Washington, Seattle, WA, USA. 3 Dept of Pathology, Chung Shan Medical and Dental University, Taichung, Taiwan
CORRESPONDENCE: W.R. Henderson Jr, Dept of Medicine, Box 356523, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195-6523, USA. Fax: 1 2066859318. E-mail: joangb@u.washington.edu
Keywords: Allergy, eosinophils, extracellular matrix, fibrosis, inflammation
Received: February 5, 2003
Accepted February 7, 2004
This study was supported by National Institutes of Health (Bethesda, MD, USA) grants AI42989 and HL73722.
Lung expression of the extracellular matrix protein, laminin, and its receptor, laminin-1 receptor, were examined in a mouse model of asthma with airway remodelling.
Ovalbumin (OVA) was administered to BALB/c mice, intraperitoneally on days 0 and 14, and intranasally periodically between days 14 and 75.
The mice developed airway eosinophil and mononuclear inflammatory cell infiltration and fibrosis. On day 76, a marked increase in total laminin was seen in the airways of OVA-treated mice compared to controls by Western blot analysis. The increased laminin expression was detected immunocytochemically in the thickened subepithelial basement membrane and around airways and blood vessels. The OVA-treated mice showed increased expression of the 1, ß1, and 1 chains of the laminin-1 isoform in monocytes, macrophages and eosinophils infiltrating the airways. Laminin-1 receptor expression was increased in inflammatory and endothelial cells in the lungs of OVA-treated mice compared to controls. Treatment of OVA-sensitised/challenged mice with dexamethasone reduced airway expression of laminin and laminin-1 receptor in OVA-treated mice but not airway hyperresponsiveness to methacholine.
Laminin deposition may be an important component of the airway remodelling observed in chronic allergic lung inflammation and is a process modulated by corticosteroids.
This article has been cited by other articles:

|
 |

|
 |
 
E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward
Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling
Eur. Respir. J.,
September 1, 2007;
30(3):
574 - 588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Lloyd and D. S. Robinson
Allergen-induced airway remodelling
Eur. Respir. J.,
May 1, 2007;
29(5):
1020 - 1032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hoberg, M. Rudert, T. Pap, G. Klein, S. Gay, and W. K Aicher
Attachment to laminin-111 facilitates transforming growth factor {beta}-induced expression of matrix metalloproteinase-3 in synovial fibroblasts
Ann Rheum Dis,
April 1, 2007;
66(4):
446 - 451.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hirano, A. Kanehiro, K. Ono, W. Ito, A. Yoshida, C. Okada, H. Nakashima, Y. Tanimoto, M. Kataoka, E. W. Gelfand, et al.
Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge
Am. J. Respir. Cell Mol. Biol.,
September 1, 2006;
35(3):
366 - 377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. R. Henderson Jr., G. K. S. Chiang, Y.-t. Tien, and E. Y. Chi
Reversal of Allergen-induced Airway Remodeling by CysLT1 Receptor Blockade
Am. J. Respir. Crit. Care Med.,
April 1, 2006;
173(7):
718 - 728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Miller, J. Y. Cho, K. McElwain, S. McElwain, J. Y. Shim, M. Manni, J. S. Baek, and D. H. Broide
Corticosteroids prevent myofibroblast accumulation and airway remodeling in mice
Am J Physiol Lung Cell Mol Physiol,
January 1, 2006;
290(1):
L162 - L169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. W. Chu, J. G. Rino, R. B. Wexler, K. Campbell, R. J. Harbeck, and R. J. Martin
Mycoplasma pneumoniae infection increases airway collagen deposition in a murine model of allergic airway inflammation
Am J Physiol Lung Cell Mol Physiol,
July 1, 2005;
289(1):
L125 - L133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Inman
Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy?
Eur. Respir. J.,
July 1, 2004;
24(1):
1 - 2.
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the European Respiratory Society.
|